MDGL Q1 2020 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$38M

Net Income

-$36M

EPS (Diluted)

$-2.34

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$411M

Total Liabilities

$26M

Stockholders' Equity

$385M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$28,000	+100.0%
Operating Income	-$38M	-$18M	-109.8%
Net Income	-$36M	-$15M	-139.6%